Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

3.144.2.213
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Nephrology
Trending Topics

Review: SGLT2 Inhibitors as a Potential Treatment for Alport Syndrome

Posted on

In this review, the authors discuss sodium-glucose co-transporter-2 (SGLT2) inhibitors as a potential treatment in Alport syndrome, a rare genetic disease characterized by kidney disease and ocular and auditory defects. There is no cure but therapeutic blockade of the renin-angiotensin-aldosterone system can slow the progression of end-stage kidney disease (ESKD).

Recent clinical trials in chronic kidney disease have shown good cardiovascular and renal outcomes in patients with diabetes mellitus treated with SGLT2 inhibitors. SGLT2 inhibitors have been found to have additional nephroprotective properties which make them a potential treatment option in progressive kidney disease.

-Advertisement-
-Advertisement-

Read the full abstract here.

Reference

Mabillard H and Sayer JA. SGLT2 inhibitors – a potential treatment for alport syndrome. Clin Sci (Lond). 2020;134(4):379-388. DOI: 10.1042/CS20191276

-Advertisement-
Related Articles
Optimizing Electronic Health Record Data for Diagnosing Rare Diseases
May 29, 2021
The American Society of Nephrology Offers Informational Webinar on New COVID-19 Guidance for Dialysis Facilities
Jun 02, 2020
Attendee at Kidney Conference Tests Positive for COVID-19
Jun 02, 2020
-Advertisement-
-Advertisement-
-Advertisement-